ESMO Congress 2026

October 23–27, 2026 · Madrid · 176 items

Madrid floor. One post is one item; several people on the same trial or drug become a heat probe. The floor is paged by day; prelude discussion sits on the prelude board. Abstracts are linked, not reprinted, and other people's slides are not posted.

Oct 22Thu

Thursday · 7 items

18:00
OncoAlert@OncoAlertScore6060
🚨 #ESMO26 GI Cancer: Top Ten by @OncoAlert 🧬 From organ preservation in dMMR rectal and gastric cancer to RAS(ON) inhibition in pancreatic cancer and bispecifics in biliary tract …
#GICANCER #CRCSMHeat 4633 likes0 replies13 reposts
14:38
DrBarbiOnc@DrBarbiOncScore6060
#ESMO2026. The ADC question I am watching this week is not which target. It is which payload, and in what order.
Heat 00 likes0 replies0 reposts
14:30
ozdogan_md@ozdogan_mdScore6060
Can an ADC move from metastatic benefit into curative-intent early breast cancer? At #ESMO26, TALENT (LBA23) will test neoadjuvant trastuzumab deruxtecan in HER2-low / HR+ early br…
LBA23 trastuzumab deruxtecan HER2Heat 21 like0 replies1 repost
14:12
ozdogan_md@ozdogan_mdScore6060
Six years into NATALEE, the key question is no longer whether adjuvant ribociclib improves iDFS. Does the benefit remain durable-and is an OS signal emerging? LBA25 at #ESMO26, l…
Same topic NATALEE · 4 people LBA25 ribociclibHeat 11 like0 replies0 reposts
10:26
SuyogCancer@SuyogCancerScore6060
5 LBAs to watch out for on day 1 in breast and GI sessions @myESMO #esmo26
Heat 106 likes0 replies4 reposts
02:00
LillyOncMed@LillyOncMedScore6060
At #ESMO2026 we’re presenting treatment persistence & clinical characteristics of patients with HR+, HER2- high-risk early breast cancer (EBC) treated with abemaciclib: from a mult…
615EP abemaciclib HER2Heat 11 like0 replies0 reposts
00:00
LillyOncMed@LillyOncMedScore6060
#ESMO2026 attendees: We invite you to explore real-world data on 3-month persistence and adherence to adjuvant abemaciclib in high-risk HR+, HER2- EBC: from ABSIDE-S. ePoster 1933…
1933EP abemaciclib HER2Heat 33 likes0 replies0 reposts

Oct 21Wed

Wednesday · 23 items

22:00
HHorinouchi@HHorinouchiScore6060
🆙#ESMO26 Rapid Oral: #LCSM Non-Mets 🔥iTHYM: Ivonescimab Plus Chemotherapy as First-Line Treatment in Recurrent/Metastatic Thymic Carcinoma: Results From the Phase II Study 🎙️Dr. Xu…
NCT06750952 4156RO ivonescimab MET #LCSMHeat 44 likes0 replies0 reposts
22:00
HHorinouchi@HHorinouchiScore6060
🆙#ESMO26 Rapid Oral: #LCSM Non-Mets 🔥SKB500 (a Novel B7-H3–Targeted Antibody-Drug Conjugate) in Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Results From a Phase…
NCT06736327 3816RO 8MO 2MO #LCSMHeat 65 likes0 replies1 repost
22:00
HHorinouchi@HHorinouchiScore6060
🆙#ESMO26 Rapid Oral: #LCSM Non-Mets 🔥LungMate-014: Neoadjuvant Toripalimab Plus Chemotherapy With or Without Tifcemalimab (Anti-BTLA Antibody) in Potentially Resectable Stage III N…
NCT05891080 2574RO toripalimab tifcemalimab #LCSMHeat 22 likes0 replies0 reposts
22:00
HHorinouchi@HHorinouchiScore6060
🆙#ESMO26 Rapid Oral: #LCSM Non-Mets 🔥ABBV-706: A First-in-Class SEZ6-Targeted Topoisomerase 1 Inhibitor (Top1i)-Antibody-Drug Conjugate (ADC) With Robust Antitumor Activity in Rela…
NCT05599984 3837RO 4MO 3MO ABBV-706 #LCSMHeat 11 like0 replies0 reposts
22:00
HHorinouchi@HHorinouchiScore6060
🆙#ESMO26 Rapid Oral: #LCSM Non-Mets 🔥THRIVE (KCSG LU23-09): Rivoceranib in Patients With Pretreated Metastatic Thymic Epithelial Tumors: Phase II Multi-Center Trial 🎙️Dr. Sehhoon P…
NCT06200233 4155RO 8MO rivoceranib #LCSMHeat 33 likes0 replies0 reposts
21:42
DrRishabhOnco@DrRishabhOncoScore6060
ESMO 2026 | TOP 10 LUNG CANCER TRIALS TO WATCH! From DLL3 bispecifics and next-generation KRAS inhibitors to novel ADCs, major lung cancer data are coming at #ESMO26. 🔥 My Top 10…
Same topic DELLPHI-305 · 5 people SAFFRON KRASCENDO DELLPHI-304 ASTRIDE tarlatamab durvalumab osimertinib savolitinibHeat 6047 likes0 replies13 reposts
21:30
HHorinouchi@HHorinouchiScore6060
🆙#ESMO26 Rapid Oral II: #LCSM Mets 🔥Combi-TED: Results of a Multicenter, Phase II, Open-Label, Randomized Trial Evaluating OSE2101 Plus Docetaxel or OSE2101 Plus Nivolumab as Secon…
NCT04884282 2661RO docetaxel nivolumab #LCSMHeat 10 likes0 replies1 repost
21:30
HHorinouchi@HHorinouchiScore6060
🆙#ESMO26 Rapid Oral II: #LCSM Mets 🔥First-Line (1L) Olomorasib + Chemoimmunotherapy (Chemo-IO) in KRAS G12C-Mutant NSCLC: Updated Results From the LOXO-RAS-20001 and SUNRAY-01 Tria…
NCT04956640 SUNRAY-01 2652RO 5MO 8MO olomorasib RAS-20001 KRASHeat 10 likes0 replies1 repost
21:30
HHorinouchi@HHorinouchiScore6060
🆙#ESMO26 Rapid Oral 2: #LCSM Mets 🔥A Phase 2 Study of CS2009, a First-in-Class PD-1/VEGF/CTLA-4 Trispecific Antibody, in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) 🎙…
NCT06741644 2616RO VEGF #LCSMHeat 42 likes0 replies2 reposts
21:30
HHorinouchi@HHorinouchiScore6060
🆙#ESMO26 Rapid Oral II: #LCSM Mets 🔥IFCT-2103 DIAL: Analysis of the Phase 2 Part of a Phase 2-3 Randomized Trial, Comparing Continuation Pembrolizumab (± Pemetrexed) up to 2 Years …
NCT05255302 2618RO pembrolizumab IFCT-2103 #LCSMHeat 84 likes0 replies4 reposts
21:30
HHorinouchi@HHorinouchiScore6060
🆙#ESMO26 Rapid Oral II: #LCSM Mets 🔥KANDLELIT-001: Calderasib (MK-1084), Alone or in Combination, for KRAS G12C-Mutant Metastatic Non-Small Cell Lung Cancer (mNSCLC) 🎙️ @nahit_send…
NCT05067283 KANDLELIT-001 2680RO 9MO 1MO calderasib pembrolizumab MK-1084Heat 128 likes0 replies4 reposts
21:00
HHorinouchi@HHorinouchiScore6060
🆙#ESMO26 Rapid Oral I: #LCSM Mets 🔥First-Line BAT8008 (TROP2-ADC) Plus BAT1308 (Anti-PD-1) for Advanced NSCLC: Results From a Multicenter Phase 2 Study 🎙️Dr. Shaodong Hong 🔢2631RO …
NCT06341114 2631RO TROP2 #LCSMHeat 00 likes0 replies0 reposts
21:00
HHorinouchi@HHorinouchiScore6060
🆙#ESMO26 Rapid Oral I: #LCSM Mets 🔥COCOON: Improving Prevention of Moderate to Severe Dermatologic Adverse Events in EGFR-Mutant Advanced NSCLC Treated With First-Line (1L) Subcuta…
NCT06120140 2700RO amivantamab lazertinib EGFR #LCSMHeat 87 likes0 replies1 repost
21:00
HHorinouchi@HHorinouchiScore6060
🆙#ESMO26 Rapid Oral I: #LCSM Mets 🔥CROWN: Characterizing Resistance Mechanisms and Predictors of Early Progression and Long-Term Response to Lorlatinib: Circulating Tumor DNA (ctDN…
NCT03052608 2636RO lorlatinib ALK #LCSMHeat 21 like0 replies1 repost
21:00
HHorinouchi@HHorinouchiScore6060
🆙#ESMO26 Rapid Oral I: #LCSM Mets 🔥FLAURA2: Analysis of On-Treatment Plasma EGFRm Dynamics and Associated Clinical Outcomes in Patients (Pts) With EGFRm Advanced NSCLC Treated With…
NCT04035486 2719RO osimertinib #LCSMHeat 1311 likes0 replies2 reposts
21:00
LillyOncMed@LillyOncMedScore6060
Attending #ESMO2026? View results from monarchE investigating the association of p27 V109G SNP zygosity with outcomes & abemaciclib treatment effect in HR+, HER2− high-risk early b…
4498P abemaciclib HER2Heat 54 likes0 replies1 repost
21:00
HHorinouchi@HHorinouchiScore6060
🆙#ESMO26 Rapid Oral I: #LCSM Mets 🔥Overall Survival (OS) Analysis of Telisotuzumab Adizutecan in Patients (Pts) With Nonsquamous Non-Small Cell Lung Cancer (NSQ NSCLC): Phase 1 Fir…
NCT05029882 2658RO 8MO 2MO telisotuzumab adizutecan EGFR METHeat 00 likes0 replies0 reposts
20:30
HHorinouchi@HHorinouchiScore6060
🆙#ESMO26 Proffered Paper: #LCSM Non-Mets 🔥DeLLphi-304: Tarlatamab in Previously Treated SCLC: Extended Follow-Up of Overall Survival From the Phase 3 Trial 🎙️ @charlesrudin 🔢3808O …
NCT05740566 DELLPHI-304 3808O 4MO tarlatamab #LCSMHeat 54 likes0 replies1 repost
20:30
HHorinouchi@HHorinouchiScore6060
🆙#ESMO26 Proffered Paper: #LCSM Non-Mets 🔥ASTRIDE: Randomized Trial of Serplulimab or Atezolizumab Plus Chemotherapy in USA Patients With Extensive-Stage Small Cell Lung Cancer 🎙️ …
NCT05468489 ASTRIDE 3809O serplulimab atezolizumab #LCSMHeat 85 likes0 replies3 reposts
20:30
HHorinouchi@HHorinouchiScore6060
🆙#ESMO26 Proffered Paper II: #LCSM Mets 🔥Dalmelitinib Plus Aumolertinib Versus Platinum-Based Chemotherapy in Advanced NSCLC Patients With MET Amplification Post EGFR TKI: A Random…
NCT06110663 2615O 4MO dalmelitinib aumolertinib MET EGFR #LCSMHeat 11 like0 replies0 reposts
20:30
HHorinouchi@HHorinouchiScore6060
🆙#ESMO26 Proffered Paper: #LCSM Non-Mets 🔥Association of Biomarkers With Efficacy in the Phase 3 KEYNOTE-671 Study of Perioperative Pembrolizumab (Pembro) Plus Neoadjuvant Chemothe…
NCT03425643 KEYNOTE-671 2519O pembrolizumab KRAS #LCSMHeat 33 likes0 replies0 reposts
20:30
HHorinouchi@HHorinouchiScore6060
🆙#ESMO26 Proffered Paper: #LCSM Non-Mets 🔥PEARLS/KEYNOTE-091: Final Analysis of Adjuvant Pembrolizumab (Pembro) in Resected Early-Stage Non–Small-Cell Lung Cancer (NSCLC): Phase 3 …
NCT02504372 KEYNOTE-091 2511O 3MO pembrolizumab #LCSMHeat 43 likes0 replies1 repost
20:00
HHorinouchi@HHorinouchiScore6060
🆙#ESMO26 Proffered Paper I: #LCSM Mets 🔥PERSEE (GFPC 01-2020): Pembrolizumab With or Without Platinum-Based Chemotherapy as First-Line Treatment in Advanced NSCLC With PD-L1 ≥50%, …
NCT04547504 2614O 9MO pembrolizumab #LCSMHeat 2919 likes0 replies10 reposts